Clinical trial
A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.
NCT00540449 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2008
- Completion date
- December 31, 2011
- Enrollment
- 694 (actual)
- Sites
- 92
Conditions
As the registry lists them; a condition with its own page is linked.
hiv infections, hiv-1, human immunodeficiency virus type 1